E156 Micro-Paper · Africa Clinical Trials

Decolonising Clinical Research

Decolonising clinical research means shifting from Africa as a data source for N...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Gini
0.732
The Gini coefficient of 0.732 indicates severe concentration, with most trials confined to a handful of nations.
Research Profile Volume Growth Phase3 Complete Diversity Equity
Decolonising Clinical Research by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
No data
Decolonising Clinical Research Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.711
Phase Distribution Africa US Europe Phase 1 11 60.2 88.2 Phase 2 20 188.3 187.4 Phase 3 52 270.3 247.4 Phase 4 12 65.1 111.8 270.3 11
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Trial Flow Global Africa Africa US Europe Egypt South Af Uganda
Enrollment Distribution Africa Reference 10000 20000 30000
Why It Matters

Decolonising clinical research means shifting from Africa as a data source for Northern analysis to Africa as a sovereign knowledge producer — a transformation that requires structural, not cosmetic, change.

In the governance and sovereignty of African clinical trials, does the pattern of decolonising clinical research reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Shannon entropy of trial allocation as the primary estimand using registry metadata for each nation. The distribution yielded a Gini coefficient of 0.732 (95% CI 340.80-3401.54), indicating severe concentration of trials among a small number of nations. Shannon entropy of the trial distribution was 2.46 bits, confirming substantial concentration beyond random variation. These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Question

In the governance and sovereignty of African clinical trials, does the pattern of decolonising clinical research reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Shannon entropy of trial allocation as the primary estimand using registry metadata for each nation.

Robustness

The distribution yielded a Gini coefficient of 0.

Interpretation

732 (95% CI 340.

Boundary

80-3401.

Extra

54), indicating severe concentration of trials among a small number of nations.

Extra

Shannon entropy of the trial distribution was 2.

Extra

46 bits, confirming substantial concentration beyond random variation.

Extra

These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence.

Extra

Interpretation is limited by the use of a single registry and the absence of non-English trial databases.